// App-Quantinova.ai

70 : Impact of Antihypertensive (AHT) Choice and Advagraf® Dose on Interstitial Fibrosis/Tubular Atrophy (IF/TA) and IF/TA Progression in Renal Allografts 24 Months Post-Transplantation (Tx).

Researchers

Presenter

  • S. Cockfield

Principal Investigators

  • D. Rush

  • S. Wilson

  • J. Howell

Medical Centers

  • University of Alberta Hospital, Edmonton, Alberta, Canada

  • Health Sciences Centre Winnipeg, Winnipeg, Canada

  • Astellas Pharma Global Development, Inc., Northbrook, IL

  • Astellas Pharma Global Development, Markham, ON, Canada

Locations

  • Canada

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Basiliximab

  • Angiotensin II

  • Tacrolimus

Outcome

  • N/A

Study Design

  • Randomized

  • Open Label

  • Multicenteric

  • Prospective

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved